Psychiatric conditions like OCD, Depression, Schizophrenia, Bipolar Disorder, ADHD, and neurological disorders like epilepsy have complex etiologies and thus management can be very challenging. Every year numerous people suffer from these disorders and the numbers of affected people are alarmingly increasing by the day. The branch of medicine dealing with these disorders, on a broader perspective is called the science of neuropsychiatry, comprising of the intertwining principles of neurology and psychiatry.

Neuropsychiatry is an evolving science and in want of specifics related to exact strategy to treat these disorders using specialized drugs, there is always a fair probability of treatment not leading to stabilization of the patient. There is always scope of error in such conditions, and it needs objectivity and evidence based approach to ensure better efficacy.

This is where Neuropharmagen comes in, it uses an individual’s genomics to find out the best possible medication (the drug as well as the dose) enhancing the likelihood of positive response. The DNA of an individual unravels the information which deciphers the response of a particular drug on that individual.

This information helps the physician in choosing the most suitable drug as well as the dosage, leading to faster and smoother stabilization of the patient.


A specialised test that lets you know, well before administration, whether or not the prescribed drug would show desired efficacy. This information improves confidence, ensures compliance and adherence to medication.

All the neuropsychiatric drugs, as enlisted in the panel have been FDA approved. The list will be updated as and when more drugs and their pharmacogenomic markers are established.
With this information, doctors can be surer of their treatment modality and patients can be much more informed about their medication.

But how does it work?


The sampling for the Neuropharmagen test is done through a CE-IVD approved Oragene tube, the tubes have to be filled with the saliva sample from the patient and the kit comes equipped with needed instructions and information required for ordering as well as the shipping instructions. The test requisition format needs to be signed by the referring physician, while the patient’s confidentiality is maintained through bar coded instructions.


On principle, it identifies the most appropriate psychotropic medication for each patient based on their individual DNA analysis, it then provides the most extensive genetic based information on drug efficiency, metabolism and possible adverse effects (based on the available pharmacogenetic information available on specialized clinical databases) and once the results are delivered to the physician, the trial and error phase is surpassed, leading to effective and optimised treatment being delivered immediately, greatly facilitating patients with severe symptoms become stabilised and have a better quality of life.

That is what motivates us at iLife Discoveries. It is the vision that one day everyone would be treated with all the available information which harbours around personalized approach and precision medicine, reducing the probabilities of adverse effects of medication and bringing stability with higher probability of positive response. The idea is to make the practice a little more practical, achievable, evidence based, personalized and placed within the reach of people who need it the most.